Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer

Gomisin A (GA) is an effective component of Schisandra. The crude extracts of Schisandra chinensis and its active ingredients have been shown to inhibit multidrug resistance in tumour cells. Reactive oxygen species (ROS) have different roles in cancer and may contribute to therapy resistance. The human ovarian cancer (OC) cell lines SKOV3 and A2780, and a mouse model of OC, were used in the present study. MTT assay, colony formation assay, flow cytometry, western blot analysis, and haematoxylin and eosin (H&E) staining were performed to determine the antitumor effect of GA and paclitaxel (PTX) in vitro and in vivo. The ROS inhibitor N-acetyl cysteine (NAC) was used to assess the mechanism underlying the chemosensitizing effects of GA. Notably, the proliferation of OC cells was inhibited by PTX, which could be enhanced by the ROS inhibitor NAC or GA. Treatment with NAC + PTX or GA + PTX enhanced the cell cycle arrest, but not apoptosis, induced by PTX. Moreover, the molecular mechanism underlying this effect may be that GA decreases the levels of ROS in ovarian cancer cells and inhibits cell cycle progression by downregulating the expression of the cell cycle proteins cyclin-dependent kinase 4 and cyclin B1. In conclusion, the combination of PTX and the ROS inhibitor GA may be a novel strategy in OC chemotherapy.

Automated summary

The study demonstrated that Gomisin A (GA) as an effective component of Schisandra can inhibit multidrug resistance in tumor cells and enhance the therapeutic effect of paclitaxel (PTX) in ovarian cancer. By reducing reactive oxygen species (ROS) levels, GA promotes PTX-induced cell cycle arrest in ovarian cancer cells both in vitro and in vivo. This novel combination therapy of PTX with the ROS inhibitor GA may offer a promising strategy for ovarian cancer chemotherapy.